| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 309.77 | 1.2% |
| Total Income | 313.73 | 0.9% |
| Expenditure | 192.04 | 6.5% |
| PBT | 121.69 | 9.2% |
| Net Profit | 90.90 | 10.4% |
| OPM | 36.17% | 3.56pp |
| NPM | 28.97% | 2.97pp |
| EPS | 54.76 | 10.4% |
Procter & Gamble Health Announces Second Quarter Results: PAT up 26% for the quarter ended December 31, 2024
12 Feb 2025 · 12 Feb 2025, 08:28 pm
Summary
Procter & Gamble Health Limited announced its financial results for the quarter ended December 31, 2024. The company reported sales of ¥ 304 crores, flat compared to the same period last year. The Profit After Tax (PAT) for the quarter was ¥ 91 crores, a 26% increase from the previous year. Excluding a one-time item in the base year, the operational PAT was up 13% versus the same period last year. The company's strategic reinforcement included strengthening its supply network. The Board declared an interim dividend of 80 per equity share for the Financial Year 2024-25.
Key Highlights
- 1
Sales remained flat at ¥ 304 crores
- 2
Profit After Tax (PAT) up 26% to ¥ 91 crores
- 3
One-time item excluded, operational PAT up 13%
- 4
Strategic reinforcement of supply network
- 5
Interim dividend of 80 per equity share declared
Management Comments
Mr. Milind Thatte
This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.
Informational and educational content only. Not investment advice.